BRPI0818065A2 - Quimioterapêutco derivado de indazol cristalino - Google Patents

Quimioterapêutco derivado de indazol cristalino

Info

Publication number
BRPI0818065A2
BRPI0818065A2 BRPI0818065A BRPI0818065A2 BR PI0818065 A2 BRPI0818065 A2 BR PI0818065A2 BR PI0818065 A BRPI0818065 A BR PI0818065A BR PI0818065 A2 BRPI0818065 A2 BR PI0818065A2
Authority
BR
Brazil
Prior art keywords
indazole
crystalline
derived chemotherapeutic
chemotherapeutic
derived
Prior art date
Application number
Other languages
English (en)
Inventor
Thomas B Borchardt
Alexander Chu-Kung
Michael J Rozema
Shailendra V Bordawekar
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40090209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0818065(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BRPI0818065A2 publication Critical patent/BRPI0818065A2/pt
Publication of BRPI0818065A8 publication Critical patent/BRPI0818065A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0818065A 2007-10-19 2008-10-16 Quimioterapêutco derivado de indazol cristalino BRPI0818065A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98123607P 2007-10-19 2007-10-19
PCT/US2008/080061 WO2009052226A1 (en) 2007-10-19 2008-10-16 Crystalline indazole-derived chemotherepeutic

Publications (2)

Publication Number Publication Date
BRPI0818065A2 true BRPI0818065A2 (pt) 2015-03-31
BRPI0818065A8 BRPI0818065A8 (pt) 2016-03-08

Family

ID=40090209

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818065A BRPI0818065A8 (pt) 2007-10-19 2008-10-16 Quimioterapêutco derivado de indazol cristalino

Country Status (24)

Country Link
US (2) US7947843B2 (pt)
EP (1) EP2195298B1 (pt)
JP (1) JP5517940B2 (pt)
KR (1) KR20100085116A (pt)
CN (1) CN101827822B (pt)
AR (1) AR068917A1 (pt)
AU (1) AU2008312529A1 (pt)
BR (1) BRPI0818065A8 (pt)
CA (1) CA2699352C (pt)
CL (1) CL2008003090A1 (pt)
CO (1) CO6280481A2 (pt)
CR (1) CR11388A (pt)
DO (1) DOP2010000115A (pt)
EC (1) ECSP10010188A (pt)
ES (1) ES2460951T3 (pt)
MX (1) MX2010004286A (pt)
PA (1) PA8800201A1 (pt)
PE (1) PE20091385A1 (pt)
RU (1) RU2010119928A (pt)
SG (1) SG185327A1 (pt)
TW (1) TW200934485A (pt)
UA (1) UA99746C2 (pt)
UY (1) UY31407A1 (pt)
WO (1) WO2009052226A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947843B2 (en) * 2007-10-19 2011-05-24 Abbott Laboratories Crystalline chemotherapeutic
US8759538B1 (en) 2013-06-13 2014-06-24 Abbvie Inc. Crystalline chemotherapeutic

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
PT1638941E (pt) 2003-05-22 2010-08-24 Abbott Lab Inibidores de quinases de indazole, benzisoxazole e benzisotiazole
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) * 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
CN101346128B (zh) 2005-10-25 2013-10-02 雅培制药有限公司 包含低水溶解度药物的配方及其使用方法
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CA2667720A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg. Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
US7947843B2 (en) * 2007-10-19 2011-05-24 Abbott Laboratories Crystalline chemotherapeutic

Also Published As

Publication number Publication date
BRPI0818065A8 (pt) 2016-03-08
SG185327A1 (en) 2012-11-29
CN101827822B (zh) 2013-06-19
MX2010004286A (es) 2010-04-30
JP2011500705A (ja) 2011-01-06
WO2009052226A1 (en) 2009-04-23
KR20100085116A (ko) 2010-07-28
UA99746C2 (ru) 2012-09-25
PA8800201A1 (es) 2009-05-15
AR068917A1 (es) 2009-12-16
US7947843B2 (en) 2011-05-24
US8486988B2 (en) 2013-07-16
ECSP10010188A (es) 2010-06-29
DOP2010000115A (es) 2010-10-15
CR11388A (es) 2010-10-05
RU2010119928A (ru) 2011-11-27
CO6280481A2 (es) 2011-05-20
CN101827822A (zh) 2010-09-08
EP2195298B1 (en) 2014-02-19
US20110196010A1 (en) 2011-08-11
US20090118344A1 (en) 2009-05-07
JP5517940B2 (ja) 2014-06-11
CL2008003090A1 (es) 2009-11-27
ES2460951T3 (es) 2014-05-16
UY31407A1 (es) 2009-05-29
EP2195298A1 (en) 2010-06-16
CA2699352C (en) 2016-06-21
AU2008312529A1 (en) 2009-04-23
TW200934485A (en) 2009-08-16
PE20091385A1 (es) 2009-11-12
CA2699352A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
BRPI0813500A2 (pt) Compostos antivirais
BRPI0815042A2 (pt) Compostos de pirazol
DK2185567T3 (da) Substituerede bicyclolactam-forbindelser
BRPI0821086A2 (pt) Compostos inseticidas
DK3354267T3 (da) Stabiliseret sulforaphan
ATE542825T1 (de) Substituierte piperidino-dihydrothienopyrimidine
BRPI0813707A2 (pt) Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
BRPI0817935A2 (pt) Derivados de biarila
BRPI0812155A2 (pt) derivados de espiroindolinona
DK2154967T3 (da) Pyrimidinderivater
BRPI0811264A2 (pt) Compostos
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0812518A2 (pt) Derivados de indazolamida
BRPI0812803A2 (pt) Dessalinização
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
BRPI0814760A2 (pt) Parafuso de rebitação
BRPI0814424A2 (pt) Compostos heterociclila
FI20075851A0 (fi) Muodostusosa
BRPI0809996A2 (pt) Compostos
BRPI0814718A2 (pt) Derivados de isoxazol-imidazol
BRPI0815181A2 (pt) Compostos
BRPI0811214A2 (pt) Derivados de pirazolona

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B25A Requested transfer of rights approved

Owner name: ABBVIE INC. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.